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ABSTRACT
Objective: Hypertension is an important worldwide public health challenge because of its high frequency and concomitant risks of cardiovascular 
and kidney diseases. Left ventricular hypertrophy (LVH) is defined as an increase in the mass of the LV, which can be secondary to an increase in wall 
thickness, an increase in cavity size, or both. Relevant study reported that LVH is one of the major and independent risk factors for coronary artery 
disease, heart failure, serious dysrhythmias, and sudden death. Thus, regression of LVH is a primary pharmacologic objective. The objective of this 
study is to assess the effectiveness of losartan and amlodipine in regression of LVH and to monitor the adverse effects of these drugs on monotherapy. 
The study also focused to estimate the clinical effectiveness of specified drugs in lowering hypertension.
Methods: The study conducted was retrospective, prospective, comparative study extended over 1 year on 28 patients based on inclusion and 
exclusion criteria.
Results: Both these drugs cause regression of LVH with a decrease in LV mass index value; it is seen that amlodipine is better in controlling elevated 
blood pressure (BP), especially diastolic BP. In statistical analysis, regression of LVH was found to be correlated with reduction of BP.
Conclusion: Incidence of adverse effect was found to be prominent in amlodipine group. Thus, losartan was found to be better in regressing LVH than 
amlodipine.
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INTRODUCTION
The ventricles are the chamber in the heart responsible for pumping of 
blood off the heart. The ventricle due to constant exposure to increased 
pressure is susceptible to hypertrophy called ventricular hypertrophy, 
which means the thickening of walls of ventricle in the heart. In 
general, cardiac hypertrophy is divided broadly as physiological 
hypertrophy [1], which results as a normal response to healthy 
exercise or pregnancy and pathological hypertrophy [2,3], which is 
the response to stress or disease such as hypertension, myocardial 
infarction, or neurohormonal profile. According to the physiology of 
hypertrophy, it is categorized as eccentric and concentric hypertrophy. 
Left ventricular hypertrophy (LVH) is defined as increase in mass of LV 
which predominantly results from a chronic increase in after load of 
the LVH caused by the hypertension mainly associated with increased 
peripheral resistance, although there is a genetic component called 
osteoglycan, proved to be involved in the development of particular 
pathological condition [4,5]. In hypertrophied myocardium, there 
is a reduction in density of capillaries [6], and thus, it may be more 
susceptible to effects of ischemia [7,8]. In the mechanism of LVH, the 
etiology states that it develops by a group of physiological activation 
which includes increased LV requirement, increased resistance to LV 
evacuation, and inefficient emptying of LV [9]. Pathway involved in 
response to physiological activation includes three mechanisms which 
are increasing cross bridge formation by Frank–Starling methods, 
increase in muscle mass, and neurohumoral activation.
Targeting the mechanism responsible for LVH could slow down the 
process. Factors promoting LVH are hypertension, neurohumoral 
factors, genetic influence, obesity, aortic stenosis. Symptoms appear 
as the LVH progresses and it includes dyspnea, orthopnea, chest pain, 
palpitations, dizziness, or fainting. LVH is diagnosed by method such 
as echocardiography, cardiac magnetic resonance imaging evaluation, 
and electrocardiography [10]. Earlier experiment showed that the 
sympathetic nervous system-induced LVH in number of situations 
increases LVH mass.
Most of the known action of angiotensin-II is mediated through AT1 
receptor subtype [11]. The stimulation of AT2 receptors may aggravate 
antihypertensive effect by natriuresis, but the role of AT2 receptor 
subtype in LVH patients is unknown [12]. The study of renal effect of 
losartan by Dahlof et al. put a hint on its consistent uricosuric effect. Data 
from the losartan intervention for endpoint reduction in hypertension 
study showed a significant reduction in the risk of stroke in hypertensive 
patients with LVH [13]. Evaluation of losartan in the elderly study 
substantiated that angiotensin-II antagonist losartan is as effective 
angiotensin converting enzyme (ACE) inhibitors in safe guarding 
patients from morbidity and mortality due to cardiovascular disease.
In the grounds of plethora of antihypertensive drug used in the 
treatment of LVH, the study aims to access the chemical effectiveness, 
adverse events profile, and blood pressure (BP) regulating effect of the 
drugs, losartan and amlodipine. Losartan and amlodipine are the drugs 
with better patient outcome and therapeutic profile with additional 
benefits of lesser adverse drug reaction (ADR) events and increased 
half-life in regulating hypertension in their concerned classes. Thus, 
meeting proposed objectives of the study serves to be a prominent 
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The study population included all patients diagnosed to have LVH 
with hypertension, confirmed by echocardiography, taking either 
losartan 50 mg/day or amlodipine 5 mg/day in monotherapy under 
the Cardiology Department and those who satisfied the inclusion and 
exclusion criteria were selected for the study.
Out of 62 patients diagnosed to have LVH, 33 were found to be taking 
losartan 50 mg/day or amlodipine 5 mg/day as monotherapy, of which 
five patients are were not on regular follow-up; thus, the sample size 
was confirmed to be 28 patients.
Methodology
The study was carried out after getting approval from the Research and 
Ethics Committee. The demographic details of the patients, laboratory 
data, drug therapy details including dose, frequency, duration of 
therapy, etc., were collected from the medical records as well as 
direct interview of the patients or his/her caregivers using a pre-
designed data collection form. For the baseline data, parameters such 
as interventricular septum thickness, posterior wall thickness (PWT), 
and LV internal diameter at the diastole were recorded by means of 
echocardiographic evaluation; baseline BP values also were collected 
earlier and were asked to monitor BP values once in a fortnight; 
calculation of LV mass was carried out by Devereux formula.
Indexed LV mass is calculated by dividing LV mass by body surface 
area (m2) which is termed as left ventricular mass index (LVMI).
During the follow-up therapy period of 6-8 months, LV mass and LVMI 
were again calculated to measure whether LVH regressed in the study 
patients. Adverse events occurred in the study patients were monitored 
by means of Naranjo scale.
RESULTS
The demographic details of 28 patients included in the study were 
monitored to assess the effect of losartan and amlodipine in LVH 
regression, BP regulation, and related ADRs of specific drugs based on 







Age distribution of the patients
Maximum age group of patient in study was found to be 62 years and 
minimum as 32 years. The mean age of the patients was given to be as 
50±11 years.
Gender distribution of the patient
Out of the 28 patients, the male-female ratio was found to be 3:1, i.e., the 
male patients predominate over the female patients.
Comorbidities of the patients
Dyslipidemia was the most populous comorbidity among the study 
population constituting 50% followed by diabetes mellitus 22%.
Social history (Table 1)
Number of patients on the severity of LVH
Patients were categorized by modified Simpson’s rule and the data 
obtained were as follows.
Management of LVH (Table 2)
LVH was treated with losartan 50 mg/day or amlodipine 5 mg/day, and 
the therapy was continued for 6-8 months which was categorized as 
two groups.
Effect of LVH regression
Both amlodipine and losartan used in the treatment were found to be 
effective in regressing LVH in different magnitude (Tables 3-5).
Effect on BP regulation
In accordance with LVH regression, the drugs also were effective 
in regulating hypertension thus attaining a clinical goal. After 
6-8 months of treatment, BP values were altered in both groups 
(Tables 6-8).
Table 2: Management of LVH




LVH: Left ventricular hypertrophy
Table 3: Effect of losartan





IVS (cm) 1.36±0.1 1.30±0.11 0.0001
PWT (cm) 1.2271±0.1134 1.20±0.1814 0.001
LVIDd (cm) 4.66±0.51 4.31±0.59 0.0
LV mass (g) 234.71±45.65 209.21±43.09 0.0
LVMI (g/m2) 135.5±26.98 121.36±25.83 0.0
IVS: Interventricular septum, PWT: Posterior wall thickness, LVIDd: Left 
ventricular diastolic internal diameter, LV: Left ventricular, LVMI: Left 
ventricular mass index
Table 4: Effect of amlodipine





IVS (cm) 1.37±0.09 1.29±0.08 0.001
PWT (cm) 1.27±0.1173 1.217±0.1195 0.002
LVIDd (cm) 4.76±0.36 4.59±0.35 0.001
LV mass (g) 251±51.29 230±47.68 0.0
LVMI (g/m2) 139.07±26.9 126.29±25.086 0.0001
IVS: Interventricular septum, PWT: Posterior wall thickness, LVIDd: Left 
ventricular diastolic internal diameter, LV: Left ventricular, LVMI: Left 
ventricular mass index
Table 5: Effect of losartan versus amlodipine on LVH regression




IVS (cm) 0.0564±0.041 0.0735±0.063 0.002
PWT (cm) 0.02±0.03 0.053±0.039 0.001
LVIDd (cm) 0.2242±0.206 0.165±0.15 0.0
LV mass (g) 25.5±10.53 20±13.02 0.0
LVMI (g/m2) 14.143±6.1 12.286±3.09 0.0001
IVS: Interventricular septum, PWT: Posterior wall thickness, LVIDd: Left 
ventricular diastolic internal diameter, LV: Left ventricular, LVMI: Left 
ventricular mass index, LVH: Left ventricular hypertrophy
Table 1: Social history
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Correlation of BP value with LVMI (Tables 9 and 10)
effect [17]. The steering factors for the development of cardiac 
hypertrophy, other than chronic shoot up in pressure or volume 
overload, are elevation in plasma levels of ACE, plasma aldosterone 
levels, angiotensin concentration. The risk of cardiovascular morbidity 
and mortality increases in geometric progression if both LVH and 
hypertension persist in patients. The duration of the study was 6 months 
which is similar to the study conducted by Nalbantgil et al. [18]. In a 
comparative trial between losartan and atenolol conducted by Dahlof 
Table: 6: Effect of losartan on BP regulation
Parameter Before therapy After therapy p value
SBP 147.36±9.44 137.43±10.06 0.0
DBP 87.14±3.98 85.43±4.67 0.001
BP: Blood pressure, SBP: Systolic blood pressure, DBP: Diastolic blood pressure
Table: 7: Effect of amlodipine on BP regulation
Parameter Before therapy After therapy p value
SBP 148.5±14.66 139.7±15.13 0.0
DBP 89.57±7.24 84.36±6.22 0.017
BP: Blood pressure, SBP: Systolic blood pressure, DBP: Diastolic blood pressure
Table 8: Losartan versus amlodipine in BP




SBP (mmHg) 9.929±5.79 8.786±8.322 0.04
DBP (mmHg) 1.7143±2.812 5.214±5.899 0.002
BP: Blood pressure, SBP: Systolic blood pressure, DBP: Diastolic blood pressure
Table 10: Correlation of DBP values with LVMI
Drug LVMI (g/m2) DBP (mmHg) Correlation
Losartan 121.36±25.83 85.43±4.67 0.21
Amlodipine 126.29±25.086 84.36±6.22 0.41
LVMI: Left ventricular mass index, DBP: Diastolic blood pressure
Fig. 1: Gender distribution of the patient
Fig. 2: Number patients on the severity of left ventricular 
hypertrophy. X-axis represents the severity of left ventricular 
hypertrophy while the Y-axis represents the number of patients
Fig. 3: Age distribution. X-axis indicates the age group while the 
Y-axis indicates the number of patients
Table 9: Correlation of SBP values with LVMI
Drug LVMI (g/m2) SBP (mmHg) Correlation
Losartan 121.36±25.83 137.43±10.06 0.17
Amlodipine 126.29±25.086 139.7±15.13 0.2
LVMI: Left ventricular mass index, SBP: Systolic blood pressure
Adverse events
Twenty-eight patients had been monitored for any adverse events, 
specifically due to drugs losartan or amlodipine in the course of the 
study. Among the whole study sample, 2, i.e., 14% of patients taking 
amlodipine complained of peripheral edema, whereas in the losartan 
group, no one complained of any adverse events.
DISCUSSION
Hypertensive LV is a risk factor for coronary artery disease, heart failure, 
arrhythmias, and sudden death [14]. Therefore, regression of LVH is an 
important pharmacological objective. The goal of the present study was 
to compare the effect of angiotensin-II type 1 receptor blockers losartan 
against calcium channel blockers amlodipine in controlling LVH.
Generally,	 LVH	 is	 more	 predominant	 in	 males	 than	 in	 females	
(Figs. 1 and 2), which was comparable with demographic of Thürmann 
et al.’s [15] study. Most number of the patients was in the age 
group 50-59 years and least number of patients was under the age 
group of 30-39 years (Fig. 3). Dyslipidemia was the most populous 
comorbidity among the study population constituting 50% followed by 
diabetes mellitus 22% (Fig. 4). The prevalence of LVH has recently been 
estimated with a sitting diastolic BP (DBP) up to 115 mmHg [16].
The degree of regression of LVH by antihypertensive drugs seems 
different and independent from their magnitude of antihypertensive 
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et al. after 36 weeks of treatment with losartan, regression in LVMI was 
similar to this study [19]. There was observed a significant reduction in 
values of interventricular septum, PWT, LV diastolic internal diameter, 
and LVMI in both losartan group and amlodipine group. Indexed LV 
mass reduced in both groups by 6 months; effects of reducing LVMI in 
losartan study group was found to be more effective than amlodipine 
study group, which was more comparable with the results of Fogari 
et al.’s study [20] (Table 5).
As per Levy et al.’s study [21], there was a significant decrease in both 
the study group, wherein systolic BP (SBP) reduced more in losartan 
group and DBP reduction was seen more in amlodipine group (Table 8). 
Effect of renin-angiotensin-aldosterone system blockade by angiotensin 
receptor antagonist or ACE inhibitors was seemed to have a prominent 
effect in regressing LVH. Correlation between SBP and LVMI was found 
to be 0.17 and 0.2 in losartan and amlodipine, respectively (Table 9); 
correlation between DBP and LVMI was found to be 0.21 in losartan 
patients and 0.41 in amlodipine patients (Table 10). The ADR events 
of both groups were monitored and it was observed that only patients 
in amlodipine group experienced ADR such as peripheral edema [22], 
which was comparable with ADR occurred in Rosendorff et al.’s [23] 
study.
CONCLUSION
The study was focused to assess the clinical effectiveness of losartan 
and amlodipine in regressing LVH in patients with hypertension. A total 
of 28 patients completed the study, of which 14 were on losartan and 
14 were on amlodipine. Both of these cause regression in LVH with 
decreases in the LVMI value. In losartan group, LVMI was reduced by 
magnitude of 14 g/m2, and in amlodipine group, it was reduced by 
magnitude of 12 g/m2. Thus, losartan is considered to be the best in 
regressing LVH compared with amlodipine in a period of 6-8 months. 
The drugs were also monitored for the effect in regulating hypertension. 
Both losartan and amlodipine reduced mean BP value. Of both the drugs, 
it was assessed that amlodipine is better in controlling elevated BP 
especially DBP. Both the drugs reactions brought regression of LVH in 
6 months. For a better clinical outcome, the drug has to be continued for 
a comparatively longer period. While monitoring ADR, 2 patients who 
were on amlodipine complained on adverse effects such as peripheral 
edema, whereas no adverse effect was reported in losartan group. This 
never implies that losartan is free of adverse events because the study 
population of this particular study was small.
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